Clinical Trials Logo

Infections, Herpesviridae clinical trials

View clinical trials related to Infections, Herpesviridae.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT00116844 Completed - Clinical trials for Infections, Herpesviridae

VALTREX Once Daily For Viral Shedding In Herpes Simplex Virus 2 (HSV-2) Seropositive Subjects. VALTREX® Tablet is a Trademark of GlaxoSmithKline Group of Companies.

Start date: March 29, 2005
Phase: Phase 4
Study type: Interventional

Eligible subjects will be randomized to receive VALTREX® tablet 1g or placebo once daily for 60 days in a two-way crossover study with a washout period of 7 days between treatment periods.